NCT07130500

Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization

Enrolling by Invitation
NAAges 18–65InterventionalTreatment
Stanford University
~1,000 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Financial incentives for adherence to long-acting injectable medicationStandard of care with monthly surveys

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence to antipsychotic medication
Measured over From start of study to end of study 12 months later; for follow-up, for 12 months after end of study.
+1 more outcome measured
Schizophrenia Disorder
Schizoaffective Disorder
Bipolar Disorder (BD)
Substance Use Disorder (SUD)
5 sites across 1 states
Pennsylvania5
  • Antoine Douaihy, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
  • Valentin Bolotnyy, PhD · PRINCIPAL_INVESTIGATOR · Stanford University

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of schizophrenia, schizoaffective disorder, and/or bipolar disorder
Recent (within 12 months) involuntary hospitalization or high risk of future hospitalization
Eligible for medication (antipsychotic or SUD-related) with an LAI formulation
Allegheny County, PA resident
Receiving or assigned to treatment at clinics participating in this study

Exclusion

Lack of injectable formulation for prescribed medication
Aged under 18 or 65 or older
  • Adherence to antipsychotic medicationFrom start of study to end of study 12 months later; for follow-up, for 12 months after end of study.

    Proportion of days covered by medication

  • Involuntary hospitalizationFrom start of study to end of study 12 months later; for follow-up, for 12 months after end of study.

    Binary indicator for whether or not individual was involuntarily hospitalized